

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

**(1) POLL RESULTS OF THE 2023 EXTRAORDINARY GENERAL MEETING
HELD ON 29 DECEMBER 2023;
(2) APPOINTMENT OF THE SECOND SESSION OF THE BOARD;
AND
(3) APPOINTMENT OF THE SECOND SESSION OF
THE SUPERVISORY COMMITTEE**

References are made to the notice (the “**EGM Notice**”) of the 2023 extraordinary general meeting (the “**EGM**”), and the circular (the “**Circular**”) of Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”) dated 12 December 2023. Capitalised terms used herein shall, unless otherwise defined, have the same meanings as those defined in the Circular.

The Board is pleased to announce that the Company convened and held the EGM at 1601 Zhangdong Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, PRC on Friday, 29 December 2023. The proposed resolutions as set out in the EGM Notice were duly passed by way of poll at the EGM.

The EGM was convened by the Board. Mr. Sun Hongbin, a non-executive Director and the chairman of the Board, was the chairman of the EGM and presided over the EGM. Six of the seven Directors of the first session of the Board, namely Dr. He Chao, Mr. Sun Hongbin, Mr. Chen Chen, Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong attended the EGM in person or by electronic means while Mr. Sun Xin, non-executive Director, was unable to attend the EGM due to other business commitment.

POLL RESULTS OF THE EGM

As at the date of the EGM, the total number of Shares in issue was 958,593,831. MicroPort through its indirectly wholly owned subsidiary Shanghai Latent holds 483,767,176 Shares. Pursuant to a concert party agreement, Shanghai Latent and Shanghai Qingzhen are parties acting-in-concert. Thus, the 16,963,831 Shares held by Shanghai Qingzhen and the 483,767,176 Shares held by Shanghai Latent, representing approximately 52.24% of the total issued share capital of the Company, shall abstain from voting at the EGM on the resolutions in relation to the 2024 Sales Framework Agreement, 2024 Master Products Procurement Agreement and 2024 Master Services Procurement Agreement and the transactions contemplated thereunder (including the proposed annual caps). Accordingly, the total number of Shares entitling the Independent Shareholders to attend and vote on resolutions numbered 1 to 3 at the EGM was 457,862,824 Shares. The total number of Shares entitling the Shareholders to attend and vote on resolutions numbered 4 to 12 was 958,593,831.

Shareholders and Independent Shareholders (including their respective proxies and authorised representatives), holding a total of 779,557,181 Shares and 295,790,005 Shares, respectively, representing approximately 81.3% and 64.6% of the total number of Shares entitling the Shareholders and Independent Shareholders to attend and vote, were present at the EGM, respectively.

The poll results in respect of the resolutions proposed at the EGM were as follows:

Ordinary Resolutions		Number of Votes and Percentage of Total Number of Votes		
		FOR	AGAINST	ABSTAIN
1.	<p>“THAT</p> <p>(a) the 2024 sales framework agreement entered into between the Company and MicroPort Scientific Corporation dated 6 December 2023 in relation to the sale and purchase of, among others, certain surgical robot equipment and supporting accessories and consumables for surgical robot equipment (the “2024 Sales Framework Agreement”), a copy of which is tabled at the meeting and marked “A” and initialed by the chairman of the meeting for identification purpose, the terms thereof and the continuing connected transaction contemplated thereunder be and are hereby approved, ratified and confirmed;</p> <p>(b) the proposed annual caps set out in the 2024 Sales Framework Agreement be and is hereby approved; and</p> <p>(c) any one director of the Company be and is hereby authorised for and on behalf of the Company to execute all such other documents, instruments and agreements and to do all such acts or things deemed by him to be incidental to, ancillary to or in connection with the matters contemplated in the 2024 Sales Framework Agreement.”</p>	<p>295,728,505 (99.979208%)</p>	<p>0 (0.000000%)</p>	<p>61,500 (0.020792%)</p>

Ordinary Resolutions		Number of Votes and Percentage of Total Number of Votes		
		FOR	AGAINST	ABSTAIN
2.	<p>“THAT</p> <p>(a) the 2024 master products procurement agreement entered into between the Company and MicroPort Scientific Corporation dated 6 December 2023 in relation to the procurement of certain materials and products mainly for use in research and development, production and operation (the “2024 Master Products Procurement Agreement”), a copy of which is tabled at the meeting and marked “B” and initialed by the chairman of the meeting for identification purpose, the terms thereof and the continuing connected transaction contemplated thereunder be and are hereby approved, ratified and confirmed;</p> <p>(b) the proposed annual caps set out in the 2024 Master Products Procurement Agreement be and is hereby approved; and</p> <p>(c) any one director of the Company be and is hereby authorised for and on behalf of the Company to execute all such other documents, instruments and agreements and to do all such acts or things deemed by him to be incidental to, ancillary to or in connection with the matters contemplated in the 2024 Master Products Procurement Agreement.”</p>	<p>295,728,505 (99.979208%)</p>	<p>0 (0.000000%)</p>	<p>61,500 (0.020792%)</p>

Ordinary Resolutions		Number of Votes and Percentage of Total Number of Votes		
		FOR	AGAINST	ABSTAIN
3.	<p>“THAT</p> <p>(a) the 2024 master services procurement agreement entered into between the Company and MicroPort Scientific Corporation dated 6 December 2023 in relation to the procurement of certain services, including but not limited to cleaning and packaging services, sterilization services, product testing services, animal test services, administrative support services and marketing activity support and commercial promotion services (the “2024 Master Services Procurement Agreement”), a copy of which is tabled at the meeting and marked “C” and initialed by the chairman of the meeting for identification purpose, the terms thereof and the continuing connected transaction contemplated thereunder be and are hereby approved, ratified and confirmed;</p> <p>(b) the proposed annual caps set out in the 2024 Master Services Procurement Agreement be and is hereby approved; and</p> <p>(c) any one director of the Company be and is hereby authorised for and on behalf of the Company to execute all such other documents, instruments and agreements and to do all such acts or things deemed by him to be incidental to, ancillary to or in connection with the matters contemplated in the 2024 Master Services Procurement Agreement.”</p>	295,728,505 (99.979208%)	0 (0.000000%)	61,500 (0.020792%)
4.	To consider and approve the appointment of Dr. He Chao as an executive director of the Company and to authorise the board of directors of the Company (the “Board”) to fix his remuneration.	779,269,165 (99.963054%)	226,516 (0.029057%)	61,500 (0.007889%)
5.	To consider and approve the appointment of Mr. Sun Hongbin as a non-executive director of the Company and to authorise the Board to fix his remuneration.	779,322,300 (99.969870%)	173,381 (0.022241%)	61,500 (0.007889%)

Ordinary Resolutions		Number of Votes and Percentage of Total Number of Votes		
		FOR	AGAINST	ABSTAIN
6.	To consider and approve the appointment of Mr. Chen Xinxing as a non-executive director of the Company and to authorise the Board to fix his remuneration.	703,252,425 (90.211782%)	1 (0.000000%)	76,304,755 (9.788218%)
7.	To consider and approve the appointment of Mr. Chen Chen as a non-executive Director of the Company and to authorise the Board to fix his remuneration.	779,495,680 (99.992111%)	1 (0.000000%)	61,500 (0.007889%)
8.	To consider and approve the appointment of Dr. Li Minghua as an independent non-executive Director of the Company and to authorise the Board to fix his remuneration.	779,495,680 (99.992111%)	1 (0.000000%)	61,500 (0.007889%)
9.	To consider and approve the appointment of Mr. Yao Haisong as an independent non-executive Director of the Company and to authorise the Board to fix his remuneration.	767,936,344 (98.509303%)	11,559,337 (1.482808%)	61,500 (0.007889%)
10.	To consider and approve the appointment of Mr. Mui Wing Hong as an independent non-executive Director of the Company and to authorise the Board to fix his remuneration.	779,282,529 (99.964768%)	213,152 (0.027343%)	61,500 (0.007889%)
11.	To consider and approve the appointment of Dr. Zhang Jie as a supervisor of the Company and to authorise the supervisory committee of the Company (the “ Supervisory Committee ”) to fix his remuneration.	779,495,680 (99.992111%)	1 (0.000000%)	61,500 (0.007889%)
12.	To consider and approve the appointment of Ms. Zhang Lihong as a supervisor of the Company and to authorise the Supervisory Committee to fix her remuneration.	769,365,580 (98.692642%)	10,130,101 (1.299469%)	61,500 (0.007889%)

In respect of the above ordinary resolutions numbered 1 to 3, as more than half of the voting rights represented by the Independent Shareholders (including their proxies and authorised representatives) attending the EGM were cast in favour of each of the resolutions numbered 1 to 3, such resolutions were duly passed as ordinary resolutions at the EGM.

In respect of the above ordinary resolutions numbered 4 to 12, as more than half of the voting rights represented by the Shareholders (including their proxies and authorised representatives) attending the EGM were cast in favour of each of the resolutions numbered 4 to 12, such resolutions were duly passed as ordinary resolutions at the EGM.

Save as disclosed, as at the date of the EGM, (i) there were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions proposed at the EGM pursuant to Rule 13.40 of the Listing Rules; (ii) none of the Shareholders were required under the Listing Rules to abstain from voting at the EGM; and (iii) none of the Shareholders had stated their intention in the Circular to vote against or to abstain from voting on the resolution proposed at the EGM.

Computershare Hong Kong Investor Services Limited, the Company's branch share registrar in Hong Kong, acted as the scrutineer for vote-taking at the EGM.

APPOINTMENT OF THE SECOND SESSION OF THE BOARD

The Board is pleased to announce that:

- Dr. He Chao has been re-elected as an executive Director for the second session of the Board;
- each of Mr. Sun Hongbin and Mr. Chen Chen has been re-elected as a non-executive Director for the second session of the Board;
- Mr. Chen Xinxing has been elected as a non-executive Director for the second session of the Board and becomes a member of the audit committee of the Board; and
- each of Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong has been re-elected as an independent non-executive Director for the second session of the Board.

Please refer to the Circular for the biographical details of the Directors and the information required to be disclosed under Rule 13.51(2) of the Listing Rules. The Directors confirmed that there is no change in their biographical details between the publication date of the Circular and the date of this announcement.

The term of the second session of the Board will be three years commencing from 29 December 2023, being the date of the EGM. The Company will enter into a service contract or an appointment letter with each of the above Directors (as the case may be).

APPOINTMENT OF THE SECOND SESSION OF THE SUPERVISORY COMMITTEE

The Supervisory Committee is pleased to announce that:

- each of Dr. Zhang Jie and Ms. Zhang Lihong has been re-elected as a shareholders representative Supervisor of the second session of the Supervisory Committee; and
- Mr. Chen Gong was elected as an employee representative Supervisor of the second session of the Supervisory Committee at the employee representatives' meeting of the Company held on 29 December 2023.

According to the Articles of Association, an employee representative Supervisor shall be elected by the employee representatives' meeting, employees union or other democratic means, which are not subject to approvals from the Shareholders.

Please refer to the Circular for the biographical details of Dr. Zhang Jie and Ms. Zhang Lihong and the information required to be disclosed under Rule 13.51(2) of the Listing Rules. The shareholders representative Supervisors confirmed that there is no change in their biographical details between the publication date of the Circular and the date of this announcement.

The biographical details of Mr. Chen Gong are set out as follows:

Mr. Chen Gong (陳功), aged 32, has served as the senior R&D manager of the Company since January 2020 and is primarily responsible for the R&D management of surgical robots of the Group. He served as the Company's mechanical R&D engineer from February 2016 to January 2020 and primarily responsible for the structural development of surgical robots.

Mr. Chen Gong graduated from Henan Engineering College in the PRC in 2013 with a bachelor's degree in mechanical design, manufacturing and automation, and graduated from Jiangsu University in the PRC in 2016 with a master's degree in mechanical engineering.

Save as disclosed above, Mr. Chen Gong has confirmed that, as at the date of this announcement, (i) he does not hold any other positions with the Company and/or any of its subsidiaries; (ii) he does not, nor did he in the past three years, hold any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (iii) he does not have any relationships with any Directors, Supervisors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) he does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, Mr. Chen Gong has confirmed that, as at the date of this announcement, there are no other matters relating to the election that are required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters need to be brought to the attention of the Shareholders.

Mr. Chen Gong will not receive any remuneration from the Group as an employee representative Supervisor.

The term of the second session of the Supervisory Committee will be three years commencing from 29 December 2023, being the date of the EGM and the employee representatives' meeting of the Company. The Company will enter into a service contract with each of the above Supervisors.

The Supervisory Committee also announces that due to expiry of term, Mr. Yuan Shuai will no longer serve as the employee representative Supervisor from 29 December 2023. Mr. Yuan Shuai has confirmed that he has no disagreement with the Supervisory Committee, and there are no other matters that need to be brought to the attention of the Shareholders.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 29 December 2023

As at the date of this announcement, the executive Director is Dr. He Chao, the non-executive Directors are Mr. Sun Hongbin, Mr. Chen Xinxing and Mr. Chen Chen, and the independent non-executive Directors are Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong.